Gene therapy for spinal muscular atrophy: the Qatari experience

Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by hypotonia, progressive muscle weakness, and wasting. Onasemnogene abeparvovec (Zolgensma(®)) is a novel gene therapy medicine, FDA-approved in May 2019 for the treatment of SMA. This study aimed to descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Hossamaldein Gaber, Ibrahim, Khalid, Elsaid, Mahmoud Fawzi, Mohamed, Reem Babiker, Abeidah, Mahmoud I. A., Al Rawwas, Azhar Othman, Elshafey, Khaled, Almulla, Hajer, El-Akouri, Karen, Almulla, Mariam, Othman, Amna, Musa, Sara, Al-Mesaifri, Fatma, Ali, Rehab, Shahbeck, Noora, Al-Mureikhi, Mariam, Alsulaiman, Reem, Alkaabi, Saad, Ben-Omran, Tawfeg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599021/
https://www.ncbi.nlm.nih.gov/pubmed/34276047
http://dx.doi.org/10.1038/s41434-021-00273-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599021/
https://www.ncbi.nlm.nih.gov/pubmed/34276047
http://dx.doi.org/10.1038/s41434-021-00273-7

Ejemplares similares